Clinical Trial

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-01; most recent amendment 2026-03-18.
Status change: Recruiting → Active, Not Recruiting 2026-03-18
Status change: Not Yet Recruiting → Recruiting 2024-12-30
Trial Details
NCT Number NCT06671379
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Non-small Cell Lung Cancer
Enrollment 498 participants
Start Date 2024-11-29
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-19